Statistics from Altmetric.com
We read with interest the article by Aggarwal et al on repository corticotropin injection (RCI) in the treatment of refractory polymyositis and dermatomyositis (PM and DM) published in the Annals of the Rheumatic Diseases.1
The authors, who are well-respected researchers in the field of myositis, have done a good job in conducting a small open-label trial of RCI in the treatment of PM/DM using validated disease activity measures and outcome measures. Whether these patients were truly ‘resistant’ is debatable, since only 3 of the 11 patients were treated with intravenous immunoglobulin (IVIG) …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.